Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Boyko

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Brain Sciences|April 17, 2020
Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not KnowMarina Kleopatra Boziki, Evangelia Kesidou, Paschalis Theotokis, et al.
Multiple Sclerosis and Related Disorders|February 16, 2021
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionalsAlexey Boyko, Christina Therapontos, Dana Horakova, et al.
The Lancet. Neurology|May 6, 2014
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyPeter A Calabresi, Bernd C Kieseier, Douglas L Arnold, et al.
Journal of Neurology|September 1, 2012
Future MS care: a consensus statement of the MS in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
The New England Journal of Medicine|October 8, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple SclerosisLudwig Kappos, Heinz Wiendl, Krzysztof Selmaj, et al.
The Lancet. Neurology|March 12, 2014
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trialLudwig Kappos, Hans-Peter Hartung, Mark S Freedman, et al.
Multiple Sclerosis and Related Disorders|February 7, 2020
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QDGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 20, 2021
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension studyPeter Rieckmann, Robert Zivadinov, Alexey Boyko, et al.
Journal of Child Neurology|May 14, 2013
Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective studySilvia N Tenembaum, Brenda Banwell, Daniela Pohl, et al.
Multiple Sclerosis and Related Disorders|May 28, 2019
Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMSGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Brain Sciences|April 17, 2020
Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not KnowMarina Kleopatra Boziki, Evangelia Kesidou, Paschalis Theotokis, et al.
Multiple Sclerosis and Related Disorders|February 16, 2021
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionalsAlexey Boyko, Christina Therapontos, Dana Horakova, et al.
The Lancet. Neurology|May 6, 2014
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyPeter A Calabresi, Bernd C Kieseier, Douglas L Arnold, et al.
Journal of Neurology|September 1, 2012
Future MS care: a consensus statement of the MS in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
The New England Journal of Medicine|October 8, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple SclerosisLudwig Kappos, Heinz Wiendl, Krzysztof Selmaj, et al.
The Lancet. Neurology|March 12, 2014
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trialLudwig Kappos, Hans-Peter Hartung, Mark S Freedman, et al.
Multiple Sclerosis and Related Disorders|February 7, 2020
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QDGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 20, 2021
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension studyPeter Rieckmann, Robert Zivadinov, Alexey Boyko, et al.
Journal of Child Neurology|May 14, 2013
Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective studySilvia N Tenembaum, Brenda Banwell, Daniela Pohl, et al.
Multiple Sclerosis and Related Disorders|May 28, 2019
Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMSGary Cutter, Antonella Veneziano, Augusto Grinspan, et al.
Pageof 7